| Published Application/Species/Sample/Dilution | Reference |
|---|
- western blot; human; 1:500; loading ...; fig 7f
| Arai S, Varkaris A, Nouri M, Chen S, Xie L, Balk S. MARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation. elife. 2020;9: pubmed publisher |
- western blot; human; loading ...; fig 6d
| Aldonza M, Ku J, Hong J, Kim D, Yu S, Lee M, et al. Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms. Sci Adv. 2020;6:eaav7416 pubmed publisher |
- western blot; human; 1:250; loading ...; fig 5b
| El Kott A, Shati A, Al Kahtani M, Alqahtani S. Acylated Ghrelin Renders Chemosensitive Ovarian Cancer Cells Resistant to Cisplatin Chemotherapy via Activation of the PI3K/Akt/mTOR Survival Pathway. Anal Cell Pathol (Amst). 2019;2019:9627810 pubmed publisher |
- western blot; human; 1:1000; loading ...; fig s4a
| Mai W, Gosa L, Daniëls V, Ta L, Tsang J, Higgins B, et al. Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma. Nat Med. 2017;23:1342-1351 pubmed publisher |
- western blot; human; 1:1000; loading ...; fig 6b
| Yue X, Zuo Y, Ke H, Luo J, Lou L, Qin W, et al. Identification of 4-arylidene curcumin analogues as novel proteasome inhibitors for potential anticancer agents targeting 19S regulatory particle associated deubiquitinase. Biochem Pharmacol. 2017;137:29-50 pubmed publisher |
- western blot; human; loading ...; fig 2
| Reuther C, Heinzle V, Nölting S, Herterich S, Hahner S, Halilovic E, et al. The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1. Neuroendocrinology. 2018;106:1-19 pubmed publisher |
- western blot; human; loading ...; fig 1a
| Kayama K, Watanabe S, Takafuji T, Tsuji T, Hironaka K, Matsumoto M, et al. GRWD1 negatively regulates p53 via the RPL11-MDM2 pathway and promotes tumorigenesis. EMBO Rep. 2017;18:123-137 pubmed publisher |
- western blot; human; 1:1000; fig 1
| Yu L, Wu W, Gu C, Zhong D, Zhao X, Kong Y, et al. Obatoclax impairs lysosomal function to block autophagy in cisplatin-sensitive and -resistant esophageal cancer cells. Oncotarget. 2016;7:14693-707 pubmed publisher |
- western blot; human; fig 1
| Le Pen J, Maillet L, Sarosiek K, Vuillier C, Gautier F, Montessuit S, et al. Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL. Cell Death Dis. 2016;7:e2083 pubmed publisher |
- western blot; human; fig 5
| Wu C, Huang K, Yang T, Li Y, Wen C, Hsu S, et al. The Topoisomerase 1 Inhibitor Austrobailignan-1 Isolated from Koelreuteria henryi Induces a G2/M-Phase Arrest and Cell Death Independently of p53 in Non-Small Cell Lung Cancer Cells. PLoS ONE. 2015;10:e0132052 pubmed publisher |
- western blot; human; fig s3
| Yang N, Gilman P, Mirzayans R, Sun X, Touret N, Weinfeld M, et al. Characterization of the apoptotic response induced by the cyanine dye D112: a potentially selective anti-cancer compound. PLoS ONE. 2015;10:e0125381 pubmed publisher |
| Seiler K, Humbert M, Minder P, Mashimo I, Schläfli A, Krauer D, et al. Hexokinase 3 enhances myeloid cell survival via non-glycolytic functions. Cell Death Dis. 2022;13:448 pubmed publisher |
| Akande O, Damle P, Pop M, Sherman N, Szomju B, Litovchick L, et al. DBC1 Regulates p53 Stability via Inhibition of CBP-Dependent p53 Polyubiquitination. Cell Rep. 2019;26:3323-3335.e4 pubmed publisher |
| Qian F, Hu Q, Tian Y, Wu J, Li D, Tao M, et al. ING4 suppresses hepatocellular carcinoma via a NF-κB/miR-155/FOXO3a signaling axis. Int J Biol Sci. 2019;15:369-385 pubmed publisher |
| Kim J, Yu L, Chen W, Xu Y, Wu M, Todorova D, et al. Wild-Type p53 Promotes Cancer Metabolic Switch by Inducing PUMA-Dependent Suppression of Oxidative Phosphorylation. Cancer Cell. 2019;35:191-203.e8 pubmed publisher |
| Ward A, Mir H, Kapur N, Gales D, Carriere P, Singh S. Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways. World J Surg Oncol. 2018;16:108 pubmed publisher |
| Bellmaine S, Ovchinnikov D, Manallack D, Cuddy C, Elefanty A, Stanley E, et al. Inhibition of DYRK1A disrupts neural lineage specificationin human pluripotent stem cells. elife. 2017;6: pubmed publisher |
| Rastogi N, Duggal S, Singh S, Porwal K, Srivastava V, Maurya R, et al. Proteasome inhibition mediates p53 reactivation and anti-cancer activity of 6-gingerol in cervical cancer cells. Oncotarget. 2015;6:43310-25 pubmed publisher |
